SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing strong momentum driven by institutional interest following a recent price target hike and anticipation surrounding potential FDA decisions on its peptide product pipeline. The community is actively debating the stock's potential for a short squeeze, with many users focused on its ability to reclaim key moving averages while others express skepticism, comparing the current price action to previous volatility cycles.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently driving intense community discussion following reports of a partnership with Shift4 Payments, which has sparked speculation about broader enterprise software adoption. While bulls emphasize the company's expanding role in AI-driven data analytics and government contracts, bears remain focused on valuation concerns and the stock's recent choppy price action within a wider consolidation phase.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors anticipate the imminent release of Phase 3 VELA-52 clinical trial data, which the community believes could establish the company's lead asset as the superior, best-in-class treatment for hidradenitis suppurativa. The stock is seeing significant institutional accumulation and heightened discussion regarding its potential as a prime M&A target, especially with the company's full leadership team attending the upcoming Goldman Sachs Healthcare Conference.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Market sentiment surrounding the SPY is currently dominated by intense debate over evolving Iran-U.S. peace negotiations and geopolitical tensions in the Middle East, with investors closely monitoring how these headlines impact futures and oil prices. Community discussion remains polarized, as traders weigh potential volatility from trade news and monetary policy updates against the persistent resilience of major AI-driven tech stocks.

FreeCast, Inc. operates an online video streaming platform. Its cloud entertainment platform comprises the largest aggregated library of free and pay-per-view video-on-demand, streaming channels, live events, radio stations, music videos and online games. The company was founded by William A. Mobley, Jr. on June 21, 2011 and is headquartered in Orlando, FL.

Freecast Inc - Ordinary Shares - Class A

Freecast Inc

Freecast Inc. is seeing significant momentum and intense community discussion following the announcement of a reseller agreement for Starlink Business connectivity services. Traders are actively debating the stock's parabolic price action, with many focusing on potential short squeeze dynamics while others caution against the company's underlying fundamentals and the risk of dilution.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as investors brace for the highly anticipated 80th event trigger in the REGAL Phase 3 trial, which will unblind the survival data and potentially catalyze a major acquisition. The community is intensely debating the stock's valuation, fueled by speculation regarding a multi-billion dollar buyout from big pharma players and significant upward pressure from elevated short borrow fees.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is capturing significant market attention as it prepares for its Nasdaq-100 inclusion, with investors closely watching its massive multi-billion dollar contract backlog and recent AI training benchmark records. While the community remains divided between bullish sentiment regarding its infrastructure scale and bearish concerns over debt levels and insider selling, the stock continues to be a focal point of intense debate regarding the long-term sustainability of the AI cloud computing business model.

Re is an internet-native marketplace for insurance capital. It connects eligible capital providers with fully collateralized reinsurance activity conducted through licensed insurance entities. Blockchain infrastructure makes collateral, reserves, and selected operating data verifiable onchain. RE is the governance token of the Re Protocol. It governs protocol upgrades, technical permissions, committee formation, reporting standards, incentive policy, and governance procedures. Underwriting, claims, pricing, reserve decisions, and regulated operations remain with qualified professionals and licensed entities.

RE is capturing significant attention following recent listings on major exchanges, with community members actively discussing its role in tokenizing the reinsurance market and institutional backing. Investors are closely monitoring price discovery as the token attempts to establish new support levels, weighing its real-world utility against concerns over future supply unlocks.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is gaining traction as traders debate its potential for a rebound, with the community split between those accumulating in anticipation of ecosystem expansion and others dismissing the project as a speculative gamble. This heightened interest is largely driven by persistent discussions around the token's role within Japan's blockchain infrastructure and its ability to weather broader market volatility.

BTQ Technologies Corp. engages in the business of post-quantum encryption. Its products include: QCIM, QSSN, OSS, QPoW, QRiNG. The company was founded by Nicolas Roussy Newton on Novemeber 23, 1983 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending as investors debate the impact of the company's new C$150 million At-The-Market equity program, with some viewing the dilution as a necessary step to fund R&D while others fear further stock price collapse. The community remains deeply divided, balancing excitement over the company's post-quantum cryptography pilots and hardware development against concerns regarding its lack of revenue and the volatile public feud between company leadership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should WisdomTree U.S. LargeCap Dividend ETF (DLN) Be on Your Investing Radar?

Is WisdomTree U.S. LargeCap Dividend ETF (DLN) a Strong ETF Right Now?

JP Morgan sees London office market recovery with rising rents

Investing.com -- JP Morgan has highlighted a recovery in the London office market, noting several supportive trends as demand increases against limited supply.

Citi upgrades Derwent London to "buy," sees 48% upside on rental strength

WisdomTree Trust - WisdomTree U.S. LargeCap Dividend Fund

Meta Launches Standalone AI Assistant App To Rival OpenAI, Alphabet

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$96.20
Prev Close	$96.10
Open	$96.86
Dividend Yield	N/A
50-Day Moving Average	$94.70
Beta	N/A
Avg. Volume	128,996.89
PE Ratio	N/A

52-Week High	$97.62
52-Week Low	$80.02
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

DLNWisdomTree Trust - WisdomTree U.S. LargeCap Dividend Fund

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest DLN News